Brazilian Journal of One Health · Jul 17, 2026
Pleiotropic and multisystem effects of incretin therapies in cardiometabolic and neurodegenerative diseases
By Cavalcante WMP, Brandão IDN, Zacarias GCL et al.
INTRODUCTION: Overweight and obesity have serious impacts on global health systems, being associated with high morbidity, mortality, and medical costs resulting from chronic comorbidities. GLP-1 receptor agonists (AR-GLP-1) and dual GLP-1/GIP coagonists transcend conventional glycemic control, exerting pleiotropic and prognosis-modifying effects in multiple extrapancreatic tissues. OBJECTIVE: To synthesize contemporary scientific evidence regarding the multisystem clinical impact of these therapies in the integrated management of patients with multiple comorbidities. MATERIALS AND METHODS: A comprehensive narrative review based on consultative searches of the PubMed, Embase, and CENTRAL databases, selecting phase 2 and 3 randomized clinical trials and meta-analyses of high clinical relevance. RESULTS: Overall evidence from large clinical trials demonstrated robust and sustained weight reductions, reaching mean losses of 14.9% with semaglutide (STEP 1) and up to 20.9% with tirzepatide (SURMOUNT-1). Across the cardiovascular spectrum, semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE with an HR of 0.72 in the SELECT study) and promoted marked clinical improvement in obesity-related heart failure with preserved ejection fraction (STEP-HFpEF). Additionally, tirzepatide robustly reduced the apnea-hypopnea index in obstructive sleep apnea (SURMOUNT-OSA) and attenuated hepatocellular damage in metabolic dysfunction-associated steatohepatitis (MASH). In the central nervous system, lixisenatide (LIXIPARK) demonstrated neuroprotective properties by stabilizing the progression of motor disability in the early stages of Parkinson's disease. The safety profile of all molecules proved homogeneous, being dominated by mild to moderate, self-limiting gastrointestinal disorders. CONCLUSIONS: Incretin mimetic therapies mark a profound paradigm shift, establishing themselves as a holistic and unified strategy capable of improving the prognosis and quality of life of complex patients with multisystem comorbidities.